Compare PCRX & EE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | EE |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2010 | 2022 |
| Metric | PCRX | EE |
|---|---|---|
| Price | $21.99 | $34.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $37.60 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 756.7K | 500.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.94% |
| EPS Growth | ★ 107.44 | 0.79 |
| EPS | 0.16 | ★ 1.28 |
| Revenue | $541,533,000.00 | ★ $1,228,263,000.00 |
| Revenue This Year | $9.77 | $21.88 |
| Revenue Next Year | $9.71 | $21.18 |
| P/E Ratio | $137.06 | ★ $27.02 |
| Revenue Growth | 26.04 | ★ 44.26 |
| 52 Week Low | $18.80 | $21.29 |
| 52 Week High | $27.99 | $43.18 |
| Indicator | PCRX | EE |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 39.10 |
| Support Level | $20.09 | $25.83 |
| Resistance Level | $24.65 | $43.18 |
| Average True Range (ATR) | 1.11 | 1.51 |
| MACD | -0.08 | -0.73 |
| Stochastic Oscillator | 37.21 | 10.49 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.